RFP
MPLT

Root Financial Partners’s MapLight Therapeutics MPLT Stock Holding History

Root Financial Partners’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28
Closed -$569 – 3461
2026
Q1 		$569 Buy
+28
New +$501 ﹤0.01% 2825

Other funds holding MPLT

S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
MSWMA
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 16.2% 1-Year Est. Return
MPW
MA Private Wealth San Carlos, California $671M AUM 23.37% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Root Financial Partners's MPLT Position: Q2 2026 in Review

Root Financial Partners sold out of MapLight Therapeutics (MPLT) in Q2 2026, closing a stake of 28 shares — an estimated $569 sold.

Root Financial Partners first reported a position in MPLT in Q1 2026 and held it in 1 quarter. The position peaked at $569 in Q1 2026. 12 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • Root Financial Partners reported no remaining MapLight Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 28 MapLight Therapeutics shares in Q2 2026, an estimated $569.
  • Root Financial Partners first reported a position in MapLight Therapeutics in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's MapLight Therapeutics position peaked at $569 in Q1 2026.
  • 12 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.